Updated:
Sofregen Medical Inc.
Sofregen Medical Inc. is a Medford-based regenerative medicine firm developing silk-protein products for soft-tissue repair, targeting vocal cord...
Sofregen Medical Inc.
Sofregen Medical Inc. was incorporated to commercialize silk-elastin technology derived from research at Tufts University. The company has raised venture capital from investors including Polaris Partners and Launchpad Venture Group, as disclosed in public filings. It operates as a development-stage entity without disclosed revenue or AUM. The firm's strategy centers on regenerative medicine, specifically silk-based platforms for soft-tissue repair. Its pipeline includes products for vocal cord regeneration and other ENT applications. Sofregen Medical has not publicly reported any approved products or partnerships for commercialization. Headquartered in Medford, Massachusetts, the firm employs fewer than 50 professionals, based on public records. It has not disclosed additional offices or adjacent vehicles. No recent operational events were confirmed in the public domain. Sofregen Medical's structural differentiator is its reliance on silk-elastin, a protein-based material, rather than synthetic polymers or cadaveric tissue. This approach may offer lower immunogenicity and better mechanical properties, though clinical validation remains pending.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Medford
Corporate office
Medford, United States
Sector focus
Frequently asked questions
Who leads investment decisions at Sofregen Medical?
Sofregen Medical does not publicly disclose a dedicated investment committee. The firm is privately held and likely managed by its board and executive team, which has not been named in available public sources.
What is Sofregen Medical's pipeline focus?
The firm focuses on regenerative medicine products using silk-elastin for soft-tissue repair. Its lead indication is vocal cord regeneration, with additional efforts in ENT and reconstructive surgery. No products have reached market approval as of public records.
How does Sofregen Medical source its technology?
The firm's technology originates from research at Tufts University, where silk-elastin was developed. Sofregen Medical has licensed this platform for clinical applications, as disclosed in academic and regulatory filings.
Has Sofregen Medical reported any clinical trial results?
The firm has not publicly posted clinical trial data via ClinicalTrials.gov or in peer-reviewed journals as of mid-2026. Its development stage remains preclinical or early clinical per available information.
Who are Sofregen Medical's investors?
Investors include Polaris Partners and Launchpad Venture Group, both disclosed in regulatory filings. No larger family offices or institutional investors have been publicly identified.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: